Рак молочной железы у молодых женщин
Диссертация
Показатели 5 и 10-летней выживаемости были выше у больных с полным клиническим и патоморфологическим ответом (рСК), получивших комбинированное лечение (химиотерапия + лучевая терапия). В группе «относительно молодых» и «очень молодых» больных с полным клиническим ответом 10-летняя общая выживаемость равнялась 59% и 41% соответственно, а в группе больных с частичным клиническим ответом 34% и 7… Читать ещё >
Содержание
- Глава 1. Обзор литературы
- Глава 2. Материалы и методы
- Глава 3. Результаты
Список литературы
- Кампалова-Полевая Е. Б. Рак молочной железы у молодых женщин: Автореф. дис. кан. мед. наук. // Москва. 1975. — С.З.
- Ковалев Б.Н., Старинский В. В. Эпидемиология рака молочной железы в России. // Гормонозависмые опухоли: Материалы IX Всероссийской конференции онкологов. // Санкт-Петербург. -2002. С.27−29.
- Мерабишвили В.М. Выживаемость онкологических больных. // СПб. — 2006.-С. 108, 170, 256−259.
- Мерабишвили В.М. Онкологическая служба Санкт-Петербурга. // СПб.: Медицинская пресса. 2003. — С. 144.
- Мерабишвили В.М. Злокачественные новообразования на Северо-Заподном Федеральном округе России. // СПб. 2005. — С. 19.
- Семиглазов В.Ф., Веснин А. Г. Диагностика опухолей молочной железы. // СПб. -1993.-С.24.
- Семиглазов В.Ф., Нургазиев К. Ш., Арзуманов A.C. Опухоли молочной железы (лечение и профилактика). // Алма-Ата. 2001. — С.345.
- Семиглазов В.Ф., Ржанков C.B., Мигманова Н. Ш. Отдаленные результаты лечения 3359 больных раком молочной железы // Вопр. Онкологии. -1984.-С.12, 25−30.
- Семиглазов В.Ф., Семигалзов В. В., Клецель А. Е. Неинвазивные и инвазивные опухоли молочной железы. // СПб. 2006. — С.230.
- Aebi S, Gelber S, Castigleone-Gerstsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? // Lancet. 2000. — Vol.355. — P. l 869−1874.
- Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? // J Natl Cancer Inst Monogr. 1994. -Vol.16. -P.35−42.
- Andrulis IL, Bull SB, Blackstein ME et al. neuerbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group // J Clin Oncol. 1998. — Vol.16. P. 1340−1349.
- American Joint Committee on Cancer. AJCC Cancer Staging Manual, 5th edition, Philodelphia, PA: Lippincot-Raven // 1997. P. 171−180.
- Bartheau P, Steinberg SM, Merino MJ. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation // Hum Pathol. -1998. Vol.29.- P.323−329.
- Belembaogo E., Feillel V., Chollet P. et al. Neoadjuvant chemotherapy in 126 operable breast cancers. // Eur. J. Cancer. -1992. -Vol. 28A. -p.896−900.
- Berg JW, Hutter RV: Breast cancer. // Cancer. -1995. Vol.75. -P.257−269.
- Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years follow-up // N Engl J Med. 1995. -Vol.332. — P.901−926.
- Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer // N Engl L Med. 1981. — Vol.304.- P. 10−15.
- Bonnier P, Romain S, Chaprin C et al. Age as a prognostic and biological features // Int J Cancer. 1995. — Vol.62. — P. 138−45.
- Broet P, Rochefordiere A, Scholl SM et al. Contralateral breast cancer: Annual incidence and risk parameters //J Clin Oncol. 1995. — Vol.13. — P. 1578−83.
- Budman DR, Berry DY, Cirrincione C et al. Dose and dose intensity as determinats of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B // J Natl Cancer Inst. -1998. Vol.90. — P.1205−1211.
- Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases // Cancer. 1989. -Vol.63. — P. 181−187.
- Clark RM, Whelan T, Levine M et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: An update // J Natl Cancer Inst. 1996. — Vol.88. — P. 1659−64.
- Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer // Cancer. — 1996. — Vol.77.— P.2318−24.
- Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer // Am J Epidemiol. 1990.- Vol.131.- P.961−72.
- Coates A, Assessing individual benefit. NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer // Bethesda, MD, Natl Institutes of Helth.- 2000.- P. 111−113.
- Cook LS, White E, Schwartz SM et al. A population-based study of contralateral breast cancer following a first primary breast cancer // Cancer Caus Control 1996- Vol.7.- P.382−90.
- Colditz GA. Epidemiology of breast cancer // Cancer.- 1993.- Vol.71.- P.480−9.
- Colditz GA, Willett WC, Hunter DJ et al. Family history, age and risk of breast cancer//JAMA 1993 — Vol.270.- P.338−43. «
- Colleoni M, Orvieto E, Nole F et al. Prediction of response to primary chemotherapy for operable breast cancer // J Cancer.- 1999.- Vol.35.— P.574−579.
- Colleoni M, Rotmensz N, Robertson C et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation // Ann. of Oncology 2002 — P.273−279.
- Colleoni M, Gelber RD, Gelber S et al. How to improve timing and duration of adjuvant chemotherapy // The Breast 2001.- 10 (Suppl 3).- P.101−105.
- Cox DR. Regression models and lifetables // J R Statistically Soc.- 1972.-Vol.34-P. 187−202.
- Chabner E, Nixon A, Gelman R. Family history an treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer//J Clin Oncol 1998 — Vol.16.- P.2045−51.
- Chan A, Pintilie M, Vallis K, Girourd C, Goss P. Breast cancer in women38.<35 years: Review of 1002 cases from a single institution // Annals of Oncology 2000 — Vol.11- P. 1255−1262.
- Chung M, Chung HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women // Cancer.— 1996.- Vol. 77- P.97−103.
- Clahsen PC, van de Velde CJ, Duval C te al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer // Eur J Surg Oncol.- 1999.- Vol.25— P.356−363.
- Claus EB. Genetic epidemiology of breast cancer in younger women // Monogr Natl Cancer Inst.- 1994.- Vol.16.- P.49−53.
- Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trial // Lancet.— 1998.— Vol.352.- P.930−942.
- Early Breast Cancer Trialists Collaborative Group: 2000 analysis, overview results. Fifth Meeting of the Early Breast Cacer Trialists Group, Oxford, United Kingdom // September. 2000. — P.21−23.
- Easton DF, Narod SA, Ford D et al. The genetic epidemiology of BRCA 1 // Lancet 1994.- Vol.344.- P.761 (Letter).
- Ellis IO, Schnitt SJ, Sastre-Garau X et al. Invasive breast carcinoma // Iyon. — 2005.-P. 13.
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in braest cancer: experience from a large study with long-term follow-up // Histopathology 1991- Vol.19.- P.403−410.
- ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer // Ann Oncol.— 2001.- Vol.12.— P. 1047−1048.
- Fisher B, Andarson S, Wolmark N et al. Chemotherapy with or without for patients with ER-negative breast cancer and negative nodes: Results from NSABP B23 //J Clin Oncol 2001.- Vol.19.- P.931−942.G
- Fisher B, Redmond C, Poisson R et al. Eight-year of randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer//N Engl J Med.- 1989.- Vol.320.- P.822−831.
- Fisher B. Personal contributions to progress in breast cancer research and treatment // Semin Oncol.- 1996.- Vol.23.- P.414−427.
- Fowble B, Schultz D, Overmoyer B et al. The influence of young age on outcome in early stage breast cancer // Int J Radiat Oncol Biol Phys 1994.-Vol.30- P.23−33.
- Gelber S, Coates AS, Goldhirsch A et al. Effect of pregnancy on overall survival after the diagnosis of early-stage braest cancer // J Clin Oncol.- 2001.-Vol.19- P.1671−1675.
- Goldhirsch A, Gelber RD. Patient-specific factors: young patients. In: NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer. Bethesda, MD, NIH, 2000: PP33−37:
- Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant^ chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group // Ann Oncol.- 1990.- Vol.1.- P. 183 188.
- Goldbrisch A, Gelber RD, Yothers G et al. Adjuvant therapy of very young women with breast cancer: Need for tailored treatments // J Natl Cancer Inst Monogr 2001 — Vol.30 — P.44−51.
- Goldhirsch A, Gelber RD. Patient-specific factors: young patients. In: NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer // Bethesda, MD, NIH.- 2000.- P.33−37.
- Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer // J Natl Cancer Inst 1998 — Vol.90.- P.1601−1608.
- Gottardi G, Scanzi F, Zurrida S et al. Clinical and prognostic usefulness of immunohistochemical determination of Ki-67 in breast cancer // Breast.— 1993 Vol.208.- P.33−36.
- Hankey BF, Curtis RE, Naughton MD. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the affect of radiation therapy // J Natl Cancer Inst 1983.- Vol.70.- P.797−804.
- Hankey BF, Miller B, Curtis R, Korsary C. Trends in breast cancer in younger women in contrast to older women // Monogr Natl Cancer Inst.- 1994.- Vol. 16.-P.7−14.
- Harbeck N, Dettmar P, Thomssen C et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up // Br J Cancer 1999.- Vol.80.- P.419−426.
- Harbeek N, Ross JS, Yurdseven S et al. HER2neu gene amplification by fluorescwnce in situ hybridization allows risk-group assessment in node-negative breast cancer // Int J Oncol.- 1999 Vol.14.- P.663−671.
- Hartmann L, Schaid D, Woods J et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer // N Engl J Med.— 1999- Vol.340.- P.77−84.
- Hartveit FM, Lilleng PK, Maehle BO. Efferent vascular invasion in the axillary nodes in breast carcinoma: a potent prognostic factor // Asta Oncol.— 2000.— Vol.39.-P.309−312.
- Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in braest cancer // J Clin Oncol.— 1999.-Vol.17- P. 1474−1481.
- Henderson I. Adjuvant systemic therapy for early breast cancer // Cancer.— 1994. Vol.74.- P.401−409.
- Hislop TG, Elwood JM, Coldman AJ. Second primary cancers of the breast: Incidence and risk factors // Br J Cancer.- 1984.- Vol.49.- P.79−85.
- Holli K, Isola J. Effect of age on the survival of breast cancer patients // Eur J Cancer 1997.- Vol.33.- P.425−428.
- Houlston RS, McCarter E, Parbhoo S et al. Family history and of breast cancer // J Med Genet 1992 — Vol.29.- P. 154−7.
- Jacquemier J, Seradour B, Hassoun J, Piana L. Special morphologic features of invasive mammary carcinomas in women under 40 years of age // Breast Dis.-1985- Vol.1.-P. 19−22.
- Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells // Endocrinology.- 1998 Vol.139.- P.4164−4174.
- Kaplan E, Meier P. Nonparametric estimation from incomplete observations // J Am Stat Assoc.- 1958.-Vol.53.-P.457−81.
- Kollias J, Elston CW, Ellis 10 et al. Early-onset breast cancer-histopathological and prognostic considerations // Br J Cancer.- 1997.- Vol.75.- P.1318−1323.
- Kollias J, Sibbering DM, Holland et al. Breast screening for women aged <50-results from a family history clinic // Breast.- 1995, — Vol.4.- P.265.
- Kroman N, Jensen MB, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: population based study // BMJ— 2000, — Vol.320.- P.474−478.
- Kurtz JM, Jacquenier J, Amalric R et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? // J Clin Oncol — 1990.— Vol.8.-P.591−8.
- Kurts JM, Spitalier JM, Amalric R et al. Mammary recurrences in women younger than forty // Int J Radiat Oncol Bior Phys 1988.- Vol. 15.- P.271−6.
- Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines // Cancer Treat Rev.- 1976.- Vol.3.- P. l 11−120.
- Linch HT, Watson P, Conway TA, Linch JF. Natural history and age of onset of hereditary breast cancer // Cancer.- 1992.- Vol.69.- P. 1404−7.
- Lindley C. Vasa Sh, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer // J Clin Ocol 1998 — Vol.16.- P.1380−1387.
- Lohrisch C, Di Leo A, Piccart MJ. Optimal adjuvant cytotoxic therapy for breast cancer // The Breast 2001(Suppl 3) P.106−113.
- Lundin J, Lundin M, Holli K et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study // J Clin Oncol.- 2001.- Vol.19.- P.28−36.
- Lynch HT, Conway T, Fitzgibbons R et al. Age-of-onset heterogeneity in hereditary breast cancer: Minimal clues for diagnosis // Breast Cancer Res Treat 1988- Vol.12.- P.275−85.
- Marcus JN, Watson P, Page DL, Lunch HT. Pathology and heredity of breast cancer in younger women // Monogr Natl Cancer Inst.— 1994.- Vol.16.- P.23−34.
- Marcus JN, Watson P, Page DL et al. Hereditary breast cancer: Pathobiology, prognosis and BRCA 1 and BRCA 2 gene lineage //Cancer 1996.- Vol.77-P.697−709.
- Matthews RH, McNeese MD, Montague ED, Oswald MJ. Prognostic implications or age in breast cancer patients treated with tumorectomy and irradiation or with mastectomy // Int J Radiat Oncol Biol Phys.— 1988.— Vol.14.-P.659−63.
- Mettler FA, Upton AC, Kelsey CA et al. Benefits versus risks from mammography // Cancer.- 1996.- Vol.77.- P.903−9.
- Miller AB, Baines CJ, To T, Wall C. Canadian National breast screening study: 1. Breast cancer detection and death rates among women aged 40−49 years // Can Med Assoc J 1992.- Vol.147.- P. 1459−76.
- Nakai M, Uchida K, Teuscher C. The development of male reproductive organ abnormalities after neonatal exposure to tamoxifen is genetically determined // J Androl.- 1999.- Vol.20.- P.626−634.
- National Institutes of Health Consensus Development Conference // J Natl Cancer Inst Monogr.- 2001.- Vol.30.- P. 1 -152.
- Nemoto T, Vana J, Bedwani RN et al. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons // Cancer 1980.- Vol.45.- P.2917−2924.
- Neville AM, Bettelheim R, Gelber RD et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International Breast Cancer Study Group // J Clin Oncol.- 1992.- Vol.10.- P.696−705.
- Northouse LL. Breast cancer in younger women: effects on interpersonal and family relations // J Natl Cancer Inst Monogr.- 1994 Vol.16 — P.183−190.
- Noyes RD, Spanos WJ, Montague ED. Breast cancer in women aged 30 and under // Cancer 1982 — Vol.49.- P. 1302−7.
- Orel SG, Schnall MD. High risk screening working group report // J Magnet Resonance Imag 1999.- Vol.10.- P.995−1005.
- Peterson M, Fowble B, Solin LJ. Family histoiy status as a prognostic factor for breast cancer patients treated wiyh conservative surgeiy and irradiation // Breast J 1995 — Vol.1.- P.202−9.
- Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer 11 J Nutl Cancer Inst.— 1999- Vol.91.-P.943−949.
- Pinder SE, Murray S, Ellis IO et al. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy // Cancer.- 1998.-Vol.83.- P.1529−1539.
- Pinder SE, Wencyk P, Sibbering DM et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival // Br J Cancer.- 1995.-Vol.71- P.146−149.
- Press MF, Bernstein L, Thomas PA et al. HER2neu rene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas // J Clin Oncol.- 1997.- Vol.15.- P.2894−2904.
- Recht A, Connoly JL, Schnitt SJ et al. The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy // Int J Radiat Oncol Biol Phys.- 1988.- Vol.14.- P.3−10.
- Robson M, Gilewski T, Haas B et al. BRCA-associated breast cancer in young women // J Clin Oncol.- 1998.- Vol.16.- P.1642−1649.
- Robson M, Gilewsky T, Haas B et al. BRCA-associated breast cancer in young women // J Clin Oncol.- 1998.- Vol.16.- P. 1642−9.
- Rosen PP, Oberman HA. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1993.
- Rourqet A, Campana F, Zafrani B et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up // Int Radiat Oncol Biol Phys.- 1989.- Vol.17.- P.719−25.
- Schumacher M, Schmoor C, Sauerbrei W et al. The prognostic effect of histological tumor grade in node negative breast cancer patients // Breast Cancer Res Treat.- 1993.- Vol.25.- P.235−245.
- Schnitt SJ, Abner A, Gelman R et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation // Cancer.- 1994— Vol.74.- p.1746−51.
- Shapiro CL, Recht A. Late effects of adjuvant therapy for breast cancer // Mongr Natl Cancer Inst 1994.- Vol.16.-P. 101−12.
- Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark 19 431 980 // Br J Cancer 1986.- Vol.54.- P.483−92.
- Shattuck-Eidens D, McClure M, Simard J et al. A collaborative survey of 80 mutations in the BRCA 1 breast and ovarian cancer susceptibility gene // JAMA 1995- Vol.273.-P.535−41.
- Simon R, Altman DG. Statistical aspects of prognostic factors studies in oncology // Br J Cancer 1994.- Vol.69.- P.979−85.
- Sigurdsson H, Baldetorp B, Borg A. Indicators of prognosis in node negative breast cancer //N Engl J Med.- 1990.- Vol.322 P. 1045−53.
- Sjogren S, Inganas M, Lindgren A et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers // J Clin Oncol 1998 — Vol.16.- P.462−469.
- Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2neu oncogene // Science 1987.- Vol.235.-P.177−82.
- Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk // JAMA 1993 — Vol.270.- P.1563−8.
- Smith RE, Bryant J, DeCells A et al. Acute myeloid leukemia and myelodysplastic syndrome following doxorubicin-cyclophosphamide adjuvant therapy for operablr breast cancer: The NSABP experience // Breast Cancer Treat 2001 — Vol.69.- P.209−213.
- Solin L, Fowble B, Schultz D, Goodman R. Age as a prognostic factor for patients treated with definitive irradiation for early stage breast cancer // Int Radiat Oncol Biol Phys.- 1989, — Vol.16.- P.373−81.
- Sun CC, Lenoir G, Lynch, Norad SA. In situ breast cancer and BRCA 1 // Lancet 1996.- Vol.348.- P.408.
- Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors // Cancer 1997.- Vol.79.- P. 1271−1278.
- Surveillance, Epidemiology, and End Results (SEER) Program Public-Use CD-ROM (1973−1997). National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 2000, based on the August 1999 submission.5
- Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment // J Natl Cancer Inst Monogr 1994- Vol.16- P.69−77.
- Tan AR, Swain SM. Adjuvant chemotherapy for breast cancer: An update // Semin Oncol.- 2001.- Vol.28 P.359−376.
- Taylor IW, Musgrove EA, Friedlander ML et al. The influence of age on the DNA ploidy levels of breast tumors // Eur J Cancer Clin Oncol.- 1985.— Vol.19.- P.623−8.
- Tancini G, Bonadonna G, Valagussa P et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles // J Clin Oncol 1983.— Vol.1.-P.2−10.
- Tavassoli A. World Health Organization Classification Tumours // Iyon.— 2000-P. 13.
- The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: Preliminary results from NSABP protocol B27. 24th Ann San Antonio Breast Cancer Symp // Pittsburg, PA, December.-2001.
- Thomas E, Buzdar A, Theriault R et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial // Proc Am Soc Clin Oncol.- 2000.- Vol.20 P.74a (abstr 285).
- Turchetti D, Cortesi L, Federico M et al. BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer // Eur J Cancer.- 2000.- Vol.36.- P.2083−2089.
- Velentgas P, Daling JR, Malone KE et al. Pregnancy after breast carcinoma: outcomes and influence on mortality // Cancer.- 1999.— Vol.85.- P.2424−2432.1. M09
- Velentgas P, Daling JR, Risk factors for breast cancer in younger women // Monogr Natl Cancer Inst.- 1994.- Vol.16.- P.49−53.
- Viale G, Bosari S, Mazzarol G et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients // Cancer.- 1999.-Vol.85.- P.2433−2438.
- Vogel VG. Screening younger women at risk for breast cancer // Monogr Natl Cancer Inst.- 1994.- Vol.16.- P.55−60.
- Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different // Br J Cancer.— 1996.— Vol.74.-P. 1796−1800.
- Winchester DP, Osteen RT, Menk HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age // Cancer.-1996 Vol.78.- P.1838−1843.
- Winchester DP. Breast cancer in young women // Surg Clin North Am.-1996- Vol.76.- P.279−87.